Esculentin 1a derivatives and uses thereof
The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.
1. A method for reducing the severity of microbe-induced inflammation, comprising the step of contacting a bacteria, a fungus, or an acanthamoeba with a synthetic antibacterial peptide consisting of the sequence shown in SEQ ID NO: 3, or a pharmaceutical composition comprising the antibacterial peptide, wherein said contacting step comprises an effective amount of the antibacterial peptide effective to reduce microbe-induced inflammation or inhibit growth of said bacteria, said fungus, or said acanthamoeba.
2. The method of claim 1 , wherein said synthetic antibacterial peptide reduces cytokine production induced by said bacteria, said fungus, or said acanthamoeba and increases anti-inflammatory cytokine production from host immune cells.
3. The method of claim 1 , where said bacteria is a gram negative bacteria selected from the group consisting of Escherichia coli, Salmonella, Shigella, Pseudomonas, Moraxella, Helicobacter, Stenotrophomonas, Bdellovibrio , acetic acid bacteria, Legionella, Wolbachia, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella catarrhalis, Hemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Pseudomonas aeruginosa, Helicobacter pylori, Salmonella enteritidis, Salmonella typhi and Acinetobacter baumannii.
4. The method of claim 1 , where said bacteria is a gram positive bacteria selected from the group consisting of Streptococcus, Staphylococcus, Corynebacterium, Listeris, Bacillus , and Clostridium.
5. The method of claim 1 , further comprising the step of contacting said bacteria, said fungus, or said acanthamoeba with one or more of an antibacterial compound, an anti-acanthamoebal compound, or an antifungal compound.
6. The method of claim 5 , wherein the antibacterial compound is one or more of an aminoglycoside, a beta-lactam, a cephalosporin, a quinolone, a macrolide, an oxazolidinone, an ansamycin, a sulphonamide, a tetracycline, a glycopeptide, a parahydroxy benzoic acid ester, sulfisoxazole, trimethoprim, novobiocin, daptomycin and linezolid.
7. The method of claim 5 , wherein the antifungal compound is one or more of an azole, a macrocycle, an allyl amine, an echinocandin, polygodial, ciclopirox, tolnaftate, benzoic acid, undecylenic acid, flucytosine and griseofulvin.
8. The method of claim 5 , wherein said anti-acanthamoebal compound is one or more of a ketoconazole, fluconazole, sulfadiazine, pentamidine, isethionate, amphotericin B, azithromycin, itraconazole and rifampicin.
9. The method of claim 1 , wherein said synthetic antibacterial peptide is in the form of a solid, an ointment, a gel, a liquid, an aerosol, a mist, a polymer, a contact lens, a film, an emulsion, or a suspension.
10. The method of claim 1 , wherein said pharmaceutical composition is administered topically.
11. The method of claim 1 , wherein said synthetic antibacterial peptide is incorporated into a sustained-release carrier.
12. The method of claim 11 , wherein said sustained-release carrier is selected from the group consisting of a sustained release polymer, a nanoparticle, a nanosuspension, a liposome and a microcapsule.